Birth defects and incompatibles with life pathologies outside the womb
Abstract
Congenital anomalies or congenital defects (DC) are of enormous importance. In Uruguay there is a sustained and progressive decline in infant mortality.
We know that the infant mortality rate (IMR) is a negative demographic indicator related to the level of human development and the living conditions of the population. For this reason, the social reforms promoted in recent years in the country have had a positive impact.
Among them, health reform stands out within the framework of the National Integrated Health System (SNIS), which prioritized the care of pregnant women and children in all providers in the country.
In spite of these achievements, infant mortality due to CD occupies the first place (together with prematurity, which is often caused by CD), and its rate has remained almost constant for decades. In figures means that one in four to five children under 1 year of age dies from this cause.
This article aims to be a consultation guide for doctors and obstetricians who face a couple carrying a DC, allowing access to trained counseling and psychological and human containment to facilitate the empowerment of the patient.
References
(2) Organización Mundial de la Salud. 63a Asamblea Mundial de la Salud. Ginebra, 17 -21 de mayo de 2013.
(3) Marden PM, Smith DW, McDonald MJ. Congenital anomalies in the newborn infant, including minor variations. A study of 4,412 babies by surface examination for anomalies and buccal smear for sex chromatin. J Pediatr 1964; 64:357-71.
(4) Chung CS, Myrianthopoulos NC. Congenital anomalies: mortality and morbidity, burden and classification. Am J Med Genet 1987; 27(3)):505-23.
(5) Uruguay. Banco de Previsión Social. Dirección Técnica de Prestaciones. Gerencia Salud. Unidad de Perinatología. Proyecto de centro de referencia para diagnóstico prenatal. Montevideo: BPS, 2011.
(6) Sociedad Española de Ginecología y Obstetricia. Declaración de la Comisión de Bioética de la SEGO sobre la Ley Orgánica 2/2010 de Salud Sexual y Reproductiva y de la Interrupción Voluntaria del Embarazo. Madrid: SEGO, 2010.
(7) American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 101: Ultrasonography in pregnancy. Obstet Gynecol 2009; 113(2 Pt 1):451-61.
(8) Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999; 341(20):1485-90.
(9) Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153(10):961-8.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.